基于癌症患者对自体抗原的 IgG 反应的免疫毒素-猫眼课题宝

基于癌症患者对自体抗原的 IgG 反应的免疫毒素

批准号：

9101634

负责人：

SCOTT Kendall DESSAIN

金额：

$19.9万

依托单位：

LANKENAU INSTITUTE FOR MEDICAL RESEARCH

依托单位国家：

美国

项目类别：

财政年份：

2016

资助国家：

美国

项目状态：

已结题

起止时间：

2016-04-01 至 2018-03-31

来源：

https://reporter.nih.gov/project-details/9101634

关键词：

Address Affinity Amino Acids Antibodies Antibody Response Antibody-drug conjugates Antigen Targeting Antigens Aspergillus Autoantigens B lymphocyte immortalization B-Lymphocytes Bacterial Toxins Binding Biodistribution Cancer Etiology Cancer Patient Cancer cell line Cell Line Cell surface Cells Cessation of life Characteristics Clinical Cloning Colon Carcinoma Computer Simulation Development Dose Drug Kinetics GPA33 gene Generations Human Hybrid Cells Immune system Immunoglobulin G Immunoprecipitation Immunotoxins In Vitro Life Malignant Neoplasms Malignant neoplasm of lung Measures Methods Modeling Molds Monoclonal Antibodies Mus Mutate Mycotoxins Neoplasm Metastasis Non-Small-Cell Lung Carcinoma Normal Cell Patients Performance Personal Communication Phenotype Process Protein Isoforms Proteins RNA Splicing Recombinants Research Safety Solid Neoplasm Specificity Structure T-Lymphocyte T-Lymphocyte Epitopes Testing Therapeutic Toxic effect Toxin Trastuzumab Tumor Antigens United States Xenograft Model Xenograft procedure base bevacizumab cDNA Library cancer cell cancer immunotherapy cancer stem cell cancer therapy cell killing chimeric antigen receptor cytotoxic efficacy testing glycosylation human monoclonal antibodies immunogenicity in vitro activity in vitro testing in vivo killings lymph nodes malignant breast neoplasm mouse model novel public health relevance research study response screening success tumor tumorigenesis

项目摘要

项目成果

SCOTT Kendall DESSAIN的其他基金

相似基金

相关文献

中文摘要

翻译

描述（由申请人提供）：肺癌是美国癌症死亡的主要原因，但由于缺乏已知的肺癌细胞特异性抗体靶标，基于单克隆抗体（mAb）的治疗前景尚未实现。这项研究将通过表征三种新的肺癌特异性mAb来满足这一需求，这些mAb是从癌症患者中克隆的，并且在转化为抗体药物缀合物时显示出体外细胞毒性活性。我们将把它们转化为免疫毒素，并对其进行测试，以确定它们对肺癌的特异性、安全性和有效性。

英文摘要

DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer death in the United States, but the promise of therapies based on monoclonal antibodies (mAbs) has been unrealized due to the lack of known antibody targets specific for lung cancer cells. This research will address this need by characterizing three new lung cancer-specific mAbs that were cloned from patients with cancer and have shown cytotoxic activity in vitro when converted into antibody drug conjugates. We will convert them into immunotoxins and test them for and determine their specificity, safety and efficacy against lung cancer.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文